PLUS THERAPEUTICS 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Cerenome recognized $0.7 million of net diagnostic revenue in the 3rd quarter, submitted claims for 222 CNSide tests with gross charges of approximately $1.55 million, and received approximately $0.1 million in cash collections in October.
- CNSide had 26 institutions and 45 providers ordering, compared with 13 institutions at the start of the year, and approximately 190 million covered lives, or about 80% of U.S. private payer coverage.
- Cerenome reported interim RESPECT-LM data from the first 10 patients: repeated dosing was proceeding as designed, with no dose-limiting toxicities and one grade 3 treatment-related event, nausea, that resolved in 5 days.
- One RESPECT-LM patient received 3 26.4 mCi doses, totaling 79.2 mCi, exceeding the 66 mCi maximum feasible dose from the earlier Phase 1 study; 6 patients remained on study, and 1 of 10 had leptomeningeal progression through MRI documentation at 7.5 months.
- Cerenome closed enrollment in the RESPECT-GBM Phase 2 trial after treating 32 patients at the recommended dose, versus an original plan of 34, and the RESPECT Pediatric Brain Cancer Phase 1 trial was open and enrolling.
- Quarterly total revenue was $0.7 million, compared with $1.5 million in the same quarter last year, of which $1.4 million was from grants; cost of revenue was approximately $0.9 million, research and development expense was $2.1 million, and selling, general, and administrative expense was $5.2 million.
- Operating loss was $7.5 million, compared with $4.5 million a year ago; net loss was $8.7 million, or $1.14 per share, compared with $4.4 million, or $1.03 per share, in last year's 3rd quarter.
- Cerenome ended September with $4.9 million in cash, cash equivalents, and investments, compared with $8.6 million as of June 30th; it raised just under $4 million in October and continued to have access to the $20 million royalty and financing facility announced in September.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, everyone, and welcome to Cerenome's third quarter 2026 financial results and business update conference call. All participants are in a listen-only mode. Following management's remarks, we will open the call for questions. This call is being recorded. Cerenome issued its third quarter financial results on Friday. The release is available in the investor relations section of cerenome.com. Joining us are Dr. Marc Hedrick, Cerenome's President and Chief Executive Officer, Dr. Eric Daniels, Chief Operating Officer, Russell Bradley, President and General Manager of CNSide Diagnostics, and Andrew Sims, Chief Financial Officer. During today's call, we will make forward-looking statements, including statements about CNSide orders, payer coverage and collections, our financial needs, and the timing and outcome of our REYOBIQ clinical and regulatory milestones. These statements reflect our expectations as of today. Actual results may differ materially.
Please refer to Friday's release and our SEC filings, including the risk factors described there. We will undertake no obligation to update these statements except as required by law. Dr. Hedrick, you may begin.
Thank you, Jamie. Good morning, everyone, and thank you for joining us. With me today are Russ Bradley, Eric Daniels, and Andrew Sims. On this morning's third quarter call, in addition to our usual quarterly reporting, we wanted to highlight data from our ReSPECT-LM trial, which we presented last Friday at the Society for Neuro-Oncology annual meeting in Philadelphia, as well as provide some interim commercial progress we've made with CNSide since our last call. But I'd first like to start off with a few general comments. First of all, I'm very pleased to announce that we've strengthened our leadership team with three important appointments. First, Samantha Fowlkes has joined us as Vice President of Sales. We are on track with our commercial goals thus far with a small internal team and no dedicated sales staff.
Samantha is tasked with building our commercial team as we plan for strong growth in 2027. Second, Ronnie Andrews, a member of our board of directors, has agreed to join the management team as our Chief Business Officer. Ronnie brings 35 years experience across life sciences and diagnostics. He will focus on helping the company capitalize the business, as well as expanding on our therapeutic and diagnostic partnerships. Third, Dr. Eric Daniels has been promoted to Chief Operating Officer. In this role, Eric will take on a broader operational mandate and support the increasingly integrated nature of our work across diagnostics, therapeutics, and advanced data analytics. As mentioned, our CNSide diagnostic business remains on track to meet the goals we set at the start of 2026. We expect to exit 2026 at an annualized run rate of about 1,250 tests per year.
We needed our 150 million total covered lives goal for our lead diagnostic tumor cell enumeration assay. We also remain on track to secure Medicare reimbursement in the first half of the year. Russell will go into the details and walk through our plans for the rest of the year and give a preview of 2027. We are also on track to meet our REYOBIQ clinical development goals. Most notably, we have closed enrollment in our ReSPECT-GBM phase II trial and are making steady progress enrolling our ReSPECT-LM multi-dose optimization trial. Eric will discuss the ReSPECT-LM data presented at SNO last Friday. We expect full top-line data from both trials, GBM and LM dose optimization, in mid-2027. Now I would like to turn the call over to Eric to walk through the clinical update and take you through the data presented. Eric? Thank you, Marc. Our lead asset, REYOBIQ, is a precision or targeted radiopharmaceutical for central nervous system cancers that we are advancing in the treatment of leptomeningeal metastasis, recurrent glioblastoma, and pediatric malignant gliomas.
I would like to take this quarterly opportunity to review our 2026 objectives and progress for REYOBIQ as follows. Objective number one is to define the optimal dose interval for REYOBIQ in the ReSPECT-LM phase II trial, with an anticipated interim data readout in the second half of 2026. This objective has been met with interim data presented, as Marc mentioned, at the Society for Neuro-Oncology meeting this past weekend and press release this morning. I will take a moment to review the ongoing study, interim findings, and our plans ahead.
In this multi-dose study, we administer REYOBIQ, our liposomal targeted radiopharmaceutical, directly into the LM compartment through an implanted port or reservoir, thus bypassing the blood-brain barrier. In this dose optimization phase, we are evaluating various doses and various intervals between three repeat administrations of REYOBIQ and measuring how much radiation reaches or is absorbed in the LM compartment over the course of the full treatment. The interim multi-dose findings. At the 2026 Society for Neuro-Oncology annual meeting, we reported on the first 10 patients in this study, and here are the highlights. Patients were enrolled with a confirmed diagnosis of LM with a mix of primary tumor types, including three breast, one lung, four melanoma, and two ovarian. Repeated dosing is working as designed. The 10 patients were treated across three cohorts, and dose escalation is continuing as planned.
To date, one patient received three 26.4 millicurie doses for a total of 79.2 millicuries administered. That is more than the 66 millicurie maximum feasible dose from our earlier phase I study, with no observed dose-limiting toxicity. Safety is clean so far. As I just mentioned, there have been no dose-limiting toxicities and no side effects that led to a patient to stop treatment. The one grade 3 treatment-related event was nausea, which is well-known in intrathecal delivery, that resolved in five days. The one serious adverse event, shortness of breath, was judged unrelated to the drug. Dosimetry is predictable from dose to dose. Within each dose, the radiation per millicurie varied by only 8% across repeat doses. A single 13.2 millicurie dose delivers about 40 gray to the fluid space around the brain, also consistent with our earlier study.
Importantly, bone marrow exposure, which is the cause often of dose-limiting cytopenias, stays very low. Early disease control signal is present, still descriptive. Only one of 10 patients had leptomeningeal progression through MRI documentation at 7.5 months. Three patients died of their primary cancer, not the leptomeningeal disease, and six remain on study. Several patients' CSF tumor counts fell to zero and stayed there. Overall, there was durable suppression of CSF tumor cell counts. What is next and what to watch? Enrollment continues in the shorter interval and higher dose cohorts to define a recommended multiple dose regimen. Formal efficacy endpoints, response rate, neurological, progression-free survival, overall survival, are not yet assessable given we are still early in the trial timeline. What is the path to approval for REYOBIQ in LM? Just as important as the initial data is the next steps.
At the end of our phase I meeting in November 2025, the FDA aligned with our current ongoing dose optimization design for multiple doses of REYOBIQ. At the completion of the dose optimization study, we will meet with the agency with the body of safety, dosimetry, and preliminary efficacy data and agree on a randomized phase II study. We have alignment with the FDA. This next study will include a dose randomization strategy, and we are contemplating an adaptive design to potentially include a control arm. Our aim is to emerge from the phase II randomized study with a robust dataset capable of demonstrating substantial evidence of safety and effectiveness. Candidate primary endpoints, subject to change, include neurological function and overall survival. I will now turn our attention to recurrent glioblastoma.
Our objective number 2 in 2026 was completing enrollment in the ReSPECT-GBM phase II trial for glioblastoma and conducting an end-of-phase II meeting with the FDA, with the goal of aligning on a pivotal trial design, with data expected in Q4 2026. The objective of completing enrollment has been met this past quarter. On October 29th, we announced we have closed phase II enrollment after treating 32 patients at the recommended dose. The original plan was 34, yet after reviewing the statistical impact, we determined that closing at 32 would have minimal effect on the power of the planned analysis. With ongoing data maturation and database cleaning, we expect to report top-line data from this study in mid-2027. Next steps following the data readout, including an end-of-phase II meeting with the FDA, will be data dependent.
Objective number 3 is to begin enrollment in the ReSPECT-PBC phase I trial. This objective has been met, as the trial is open and currently enrolling. We look forward to keeping people updated on the trial progress in 2027. Objective number 4 is to complete commercial manufacturing scale-up for REYOBIQ. This objective also remains in progress and on track to be completed by the end of the year. The recommendations from our Type C meeting with the FDA regarding purification, qualification, and impurity characterization are all on schedule to be completed by the end of the year, and method transfer is in process to a CDMO, and the Q4 audit is planned by the end of the year. We maintain that manufacturing scale-up and supply of REYOBIQ will readily support the clinical early, excuse me, early commercial activity.
In addition to our stated objectives, we also announced preclinical data outlining a dual mechanism of action in aggressive epithelial ovarian cancer preclinical models. The highlights include a dual MOA. REYOBIQ, in addition to its radiopharmaceutical properties, provides targeted local radiation that induces lethal DNA damage and apoptosis within 24 hours while simultaneously remodeling the tumor microenvironment. Why is this important? For immune activation. The therapy shifts immunologically cold tumors to hot ones by triggering innate immunity and reducing immunosuppressive signals like IL-10 and macrophage activity, both of which are elevated in tissue and ascites. What does this ultimately mean? There is combination potential. Pairing REYOBIQ with an anti-PD-1 checkpoint-blockade substantially boosted anti-tumor efficacy compared to single tumor or single agent, excuse me, approaches. This dual mode of action opens the door to a whole host of combination potentials with REYOBIQ, both within and even outside of the CNS.
In summary, three of our four objectives for radiotherapeutics in 2026 are completed, and the fourth remains on track for completion by the end of the year. We will continue to advance REYOBIQ, and we look forward to reading out top-line data for both the ongoing LM multi-dose and GBM studies in mid-2027. Thank you for your time, and I'll hand the call over to Russell for the CNSide update.
Thanks, Eric. Since our September 30 update, CNSide has moved from submitting claims to recognizing revenue and receiving payments. We recognized about $0.7 million of net diagnostic revenue in the third quarter, and commercial payers began paying our claims in October. Andrew will take you through the numbers. October was our strongest month so far. We were up about 15% over our third quarter monthly average, bringing us to 512 tumor cell enumeration tests year to date. Most of these, of course, are backend loaded in a year, which is consistent with our expected ramp. That growth is coming from three separate drivers: new account activation and physician adoption, growth in patient monitoring, and an expanded test menu. First, I'll go through the new accounts and physicians. 26 institutions and 45 providers are now ordering, up from 13 at the start of the year.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
7 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
